Abstract

Background: Protein-conjugate capsular polysaccharide vaccines can potentially control invasive meningococcal disease (IMD) caused by five (A, C, W, X, Y) of the six IMD-associated serogroups. Concerns raised by immunological similarity of the serogroup B capsule, to human neural cell carbohydrates, has meant that 'serogroup B substitute' vaccines target more variable subcapsular protein antigens. A successful approach using outer membrane vesicles (OMVs) as major vaccine components had limited strain coverage. In 4CMenB (Bexsero ®), recombinant proteins have been added to ameliorate this problem. Methods: Here, scalable, portable, genomic techniques were used to investigate the Bexsero ® OMV protein diversity in meningococcal populations. Shotgun proteomics identified 461 proteins in the OMV, defining a complex proteome. Amino acid sequences for the 24 proteins most likely to be involved in cross-protective immune responses were catalogued within the PubMLST.org/neisseria database using a novel OMV peptide Typing (OMVT) scheme. Results: Among these proteins there was variation in the extent of diversity and association with meningococcal lineages, identified as clonal complexes (ccs), ranging from the most conserved peptides (FbpA, NEISp0578, and putative periplasmic protein, NEISp1063) to the most diverse (TbpA, NEISp1690). There were 1752 unique OMVTs identified amongst 2492/3506 isolates examined by whole-genome sequencing (WGS). These OMVTs were grouped into clusters (sharing ≥18 identical OMVT peptides), with 45.3% of isolates assigned to one of 27 OMVT clusters. OMVTs and OMVT clusters were strongly associated with cc, genogroup, and Bexsero ® antigen variants, demonstrating that combinations of OMV proteins exist in discrete, non-overlapping combinations associated with genogroup and Bexsero ® Antigen Sequence Type. This highly structured population of IMD-associated meningococci is consistent with strain structure models invoking host immune selection. Conclusions: The OMVT scheme facilitates region-specific WGS investigation of meningococcal diversity and is an open-access, portable tool with applications for vaccine development, especially in the choice of antigen combinations, assessment and implementation.

Highlights

  • Ideal vaccines comprise a single antigenically conserved component of the target pathogen, preferably against a virulence determinant

  • There is a limited repertoire of meningococcal polysaccharide capsules associated with invasive meningococcal disease (IMD), identified as serogroups A, B, C, W, X, and Y5, potentially simplifying vaccine formulation

  • While vaccines based on one or a few capsular polysaccharides have been deployed successfully since the 1960s, with notable success achieved by proteinpolysaccharide conjugate vaccines[2], a comprehensive anti-capsular vaccine has been precluded by concerns about the safety and efficacy of formulations that include the serogroup B polysaccharide

Read more

Summary

Introduction

Ideal vaccines comprise a single antigenically conserved component of the target pathogen, preferably against a virulence determinant. Meningococcal diversity extends beyond antigen genes, with a very wide range of distinct genotypes defined by variation in ‘housekeeping genes’ that encode essential cytoplasmic metabolic functions This diversity is captured by multilocus sequence typing (MLST) approaches, including conventional MLST6, ribosomal MLST (rMLST), and core genome MLST (cgMLST)[7]. These approaches have shown that both genetic and antigenic diversity of this organism is structured into clusters of related organisms, which share a common ancestor (lineages). OMVTs and OMVT clusters were strongly associated with cc, genogroup, and Bexsero® antigen variants, demonstrating that combinations of OMV proteins exist in discrete, non-overlapping combinations associated with genogroup and Bexsero® Antigen Sequence Type This highly structured population of IMD-associated meningococci is consistent with strain structure models invoking host immune selection

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call